Fisiopatología Neonatal y del Desarrollo

Axis 1: Pulmonary protection of preterm infants

L1: Prevention and treatment of bronchopulmonary dysplasia.

L2: Non-invasive respiratory support.

L3: High-frequency oscillatory ventilation with very low volumes.

L4: Non-invasive administration of pulmonary surfactants.

L5: Aerosolised surfactant in an animal model.

Axis 2: Neonatal Brain Pathology

L1: Epigenetic mechanisms involved in neurodevelopmental disorders.

L2: Biomarkers of oxidative stress and inflammation.

L3: Study of the incidence of post-hemorrhagic hydrocephalus and associated risk factors.

L4: Evaluation of an ultrasound prognostic score in preterm infants with gestational age less than or equal to 28 weeks with periventricular venous infarction.

L5: Study of cerebral and somatic oxygenation during percutaneous closure of patent ductus arteriosus.

L6: Renal damage in patients with hypoxic-ischemic encephalopathy.

Axis 3: Neonatal imaging

L1: Lung ultrasound as a diagnostic and prognostic tool in the pulmonary pathology of the premature patient.

L2: Pulmonary ultrasound as a prognostic tool in the patient with heart disease.

L3: Lung ultrasound and establishment of CFR at birth in preterm infants.

Axis 4: Personalised Neonatal Nutrition

L1: Evaluation of additional individualised protein supplementation to preterm infants fed standard fortified human milk.

L2: Evaluation of the implementation of a personalised nutrition unit in a high complexity neonatal service.

Axis 5: Neonatal pain research.

L1: Prospective observational study to assess normal values of NIPE (parasympathetic tone) in preterm infants under 32 weeks at various times of development

L2: Study of the prevalence of prolonged pain in newborns during neonatal intensive care.

L3: Study of the efficacy of implementation of neonatal pain assessment tools.

Axis 6: COVID 19 during gestation and in newborns

L1: Clinical and immunovirological aspects of SARSCoV-2 infection in a cohort of pregnant women and newborns.

Axis 7: Congenital heart disease

L1: Management of chylothorax in cardiac surgery.

L2: Perinatal management of the newborn with complete congenital atrioventricular block. Prospective study.

L3: Study of renal damage in patients with heart disease.

Axis 8: Morbimortality in the premature patient

L1: Evolution of Mortality and Morbidity in preterm infants born before 32 weeks of gestation. Impact of changes in perinatal and neonatal management.

L2: Prospective validation by means of a statewide multicentre study (REDSAMID) of predictive models of prenatal mortality in premature infants.

L3: Magnesium sulphate: relationship with meconium ileus in newborns under 32 weeks of gestational age.

L4: Magnesium sulphate as neuroprotection.

Axis 9: Optimisation of blood product administration

L1: Value of oximetry as an indicator of the need for red cell concentrate transfusion.

Axis 10: Technological innovation

L1: Development of non-ionising neonatal imaging incubator.

Axis 11: Neonatal resuscitation training

L1: Study of the impact of periodic assessment on the retention of skills and knowledge acquired in neonatal resuscitation courses.

Axis 12: Developmental malformations

L1: Long Gap Esophageal Atresia